Maze Therapeutics Announces $150 Million Oversubscribed Private Placement to Advance Kidney and Metabolic Disease Treatments
I'm PortAI, I can summarize articles.
Maze Therapeutics, Inc. has announced a $150 million oversubscribed private placement to advance treatments for kidney and metabolic diseases. The agreement includes the sale of 4,000,002 shares at $16.25 each and 5,231,090 pre-funded warrants at $16.249 each. The funds will support the development of MZE829 and MZE782, among other initiatives. The placement is expected to close on September 12, 2025, subject to customary conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments